Abstract
The accurate assessment of disease risk among children with medulloblastoma remains a major challenge to the field of paediatric neuro-oncology. In the current study we investigated the capacity of molecular abnormalities to increase the accuracy of disease risk stratification above that afforded by clinical staging alone. 41 primary medulloblastoma tumour samples were analysed for ErbB2 receptor expression using immunohistochemistry, and for aberrations of chromosome 17 and amplification of the MYC oncogene using fluorescence in situ hybridisation. The ErbB2 receptor and deletion of 17p were detected in 80% and 49% of tumours, respectively. 17p loss occurred either in isolation (20%), or in association with gain of 17q (29%), compatible with an isochromosome of 17q. Amplification of MYC was detected in only 2 tumours. Significant prognostic factors included, ‘metastatic disease’ (P = 0.0006), ‘sub-total tumour resection’ (P = 0.007), ‘high ErbB2 receptor expression’ (P = 0.003) and ‘isolated 17p loss’ (P = 0.003). Combined analysis of clinical and molecular factors enabled greater resolution of disease risk than clinical factors alone, identifying a sub-population of patients with particularly favourable disease outcome. These data support the hypothesis that a combination of clinical and molecular factors may afford a more reliable means of assigning disease risk in patients with medulloblastoma, thereby providing a more accurate basis for targeting therapy in children with this disease. © 2001 Cancer Research Campaign www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Badiali, M, Pession, A, Basso, G, Andreini, L, Rigobello, L, Galassi, E & Giangaspero, F (1991). N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumour with c-myc amplification. Tumouri, 77, 118–121.
Bailey, CC, Gnekow, A, Wellek, S, Jones, M, Round, C, Brown, J, Phillips, A & Neidhardt, MK (1995). Prospective randomised trial of chemotherapy given before raidotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the German Society of Paediatric Oncology (GPO): SIOP II. Med Ped Oncol, 25, 166–178.
Batra, SK, McLendon, RE, Koo, JS, Castelino-Prabhu, S, Fuchs, HE, Krischer, JP, Friedman, HS, Bigner, DD & Bigner, SH (1995). Prognostic implications of chromosome 17p deletions in human medulloblastoma. J Neuro-oncol, 24, 39–45.
Biegel, JA, Janss, AJ, Raffel, C, Sutton, L, Rorke, LB, Harper, JM & Phillips, PC (1997). Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumours (medulloblastomas) of the central nervous system. Clin Cancer Res, 3, 473–478.
Cobleigh, MA, Vogel, CL, Tripathy, D, Robert, NJ, Scholl, S, Fehrenbacher, L, Wolter, JM, Paton, V, Shak, S, Lieberman, G & Slamon, DJ (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17, 2639–2648.
Cogen, PH (1991). Prognostic significance of molecular genetic markers in childhood brain tumours. Pediatr Neurosurg, 92, 245–250.
Eberhart, CG, Corn, P, Campbell, S, Burger, PC, Baylin, SB & Cohen, KJ (1999). HIC-1 hypermethylation in medulloblastoma. Presented at the International Society of Pediatric Neuro-oncology, San Francisco, (June 10–14).
Emadian, SM, McDonald, JD, Gerken, SC & Fults, D (1996). Correlation of chromosome 17p loss with clinical outcome in medulloblastoma. Clin Cancer Res, 2, 1559–1564.
Giangaspero, F, Bigner, SH, Kleihues, P, Pietsch, T & Trojanowski, J (2000). Medulloblastoma. World Health Organisation classification of tumours pathology & genetics tumours of the central nervous system, Kleihues P, Cavenee WK (eds) IARC press: Lyon
Gilbertson, RJ, Perry, RH, Kelly, PJ, Pearson, AD & Lunec, J (1997a). Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res, 57, 3272–3280.
Gilbertson, RJ, Jaros, E, Perry, RH, Kelly, PJ, Lunec, J & Pearson, AD (1997b). Mitotic percentage index: A new prognostic factor for childhood medulloblastoma. Eur J Cancer, 33, 609–615.
Gilbertson, RJ, Clifford, SC, MacMeekin, W, Mcckin, W, Wright, C, Perry, RH, Kelly, P, Pearson, AD & Lunec, J (1998). Expression of the ErbB-Neuregulin signaling network during human cerebellar development: Implications for the biology of medulloblastoma. Cancer Res, 58, 3932–3941.
Gilbertson, RJ, Hernan, R, Pearson, ADJ, Pietsch, T & Lunec, J (1999). The ErbB2 receptor represents a potential target for novel therapies in childhood medulloblastoma. Clin Cancer Res, 5, 3737
Herms, JW, Behnke, J & Bergmann, M (1997). Potential prognostic value of c-erbB-2 expression in medulloblastoma in very young children. J Ped Hematol Oncol, 19, 510–515.
Herms, J, Neidt, I, Luscher, B, Sommer, A, Schurmann, P, Schroder, T, Bergmann, M, Wilken, B, Probst-Cousin, S, Hernaiz-Driever, P, Behnke, J, Hanefeld, F, Pietsch, T & Kretzschmar, HA (2000). C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer, 89, 395–402.
Kortmann, RD, Kuhl, J, Timmermann, B, Mittler, U, Urban, C, Budach, V, Richter, E, Willich, N, Flentje, M, Berthold, F, Slavc, I, Wolff, J, Meisner, C, Wiestler, O, Sorensen, N, Warmuth-Metz, M & Bamberg, M (2000). Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomised trial HIT ‘91. Int J Radiat Oncol Biol Phys, 46, 269–279.
Mantel, N (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 50, 163–170.
Nicholson, JC, Wickramasinghe, CL, Ross, FM, Crolla, J & Ellison, DW (2000). Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridisation and fluorescence in situ hybridisation. J Clin Path: Mol Path, 53, 313–319.
Olayioye, MA, Neve, RM, Lane, HA & Hynes, N (2000). The ErbB signaling network: receptor heterodimerisation in development and cancer. EMBO, 19, 3159–3167.
Packer, RJ, Goldwein, J, Nicholson, HS, Vezina, LG, Allen, JC, Ris, MD, Muraszko, K, Rorke, LB, Wara, WM, Cohen, BH & Boyett, JM (1999). Treatment of children with medulloblastoma with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children’s Cancer Study Group study. J Clin Oncol, 17, 2127–2136.
Peto, R, Pike, MC, Armitage, P, Breslow, NE, Cox, DR, Howard, SV, Mantel, N, McPherson, K, Peto, J & Smith, PG (1977). Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer, 35, 1–39.
Scheurlen, WG, Seranski, P, Mincheva, A, Kuhl, J, Sorensen, N, Krauss, J, Lichter, P, Poustka, A & Wilgenbus, KK (1997). High-resolution mapping of chromosome arm 17p in childhood primitive neuroectodermal tumours reveals a common chromosomal disruption within the Smith-Magenis region, an unstable chromosome band 17p 11.2. Gene Chrom Cancer, 18, 50–58.
Scheurlen, WG, Schwabe, GC, Joos, S, Mollenhauer, J, Sorensen, N & Kuhl, J (1998). Molecular analysis of childhood primitive neuroectodermal tumours defines markers associated with poor clinical outcome. J Clin Oncol, 16, 2478–2485.
Schwartz, CL (1999). Long-term survivors of childhood cancer: The late effects of therapy. Oncologist, 4, 45–54.
Thomas, PR, Deutsch, M, Kepner, JL, Boyett, JM, Krischer, J, Aronin, P, Albright, L, Allen, JC, Packer, RJ, Linggood, R, Mulhern, R, Stehbens, JA, Langston, J, Stanley, P, Duffner, P, Rorke, L, Cherlow, J, Friedman, HS, Finlay, JL, Vietti, TJ & Kun, LE (2000). Low-stage medulloblastoma: Final analysis of trial comparing standard-dose with reduced dose neuraxis irradiation. J Clin Oncol, 18, 3004–3011.
Zeltzer, PM, Boyett, JM, Finlay, JL, Albright, AL, Rorke, LB, Milstein, JM, Allen, JC, Stevens, KR, Stanley, P, Li, H, Wisoff, JH, Geyer, JR, McGuire-Cullen, P, Stehbens, JA, Shurin, SB & Packer, RJ (1999). Metastasis stage, adjuvant treatment, and residual tumour are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol, 17, 832–845.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Gilbertson, R., Wickramasinghe, C., Hernan, R. et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85, 705–712 (2001). https://doi.org/10.1054/bjoc.2001.1987
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1987
Keywords
This article is cited by
-
Mutation and expression analysis in medulloblastoma yields prognostic variants and a putative mechanism of disease for i17q tumors
Acta Neuropathologica Communications (2014)
-
Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma
Child's Nervous System (2013)
-
Identification of c-myc-dependent proteins in the medulloblastoma cell line D425Med
Amino Acids (2012)
-
Novel amplifications in pediatric medulloblastoma identified by genome-wide copy number profiling
Journal of Neuro-Oncology (2012)
-
Appraisal of the current staging system for residual medulloblastoma by volumetric analysis
Child's Nervous System (2011)